TIA
LUCD icon

Traphagen Investment Advisors’s Lucid Diagnostics LUCD Stock Holding History

Traphagen Investment Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$44K Hold
58,590
– – ﹤0.01% 224
2026
Q2 		$62.7K Buy
58,590
+29,295
+100% +$31.6K ﹤0.01% 216
2026
Q1 		$33.7K Hold
29,295
– – ﹤0.01% 203
2025
Q4 		$31.9K Hold
29,295
– – ﹤0.01% 193
2025
Q3 		$29.6K Hold
29,295
– – ﹤0.01% 190
2025
Q2 		$33.7K Buy
+29,295
New +$37.8K ﹤0.01% 185

Other funds holding LUCD

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
SWA
Sax Wealth Advisors Parsippany, New Jersey $3.5B AUM 13.73% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Traphagen Investment Advisors's LUCD Position: Q3 2026 in Review

Traphagen Investment Advisors held its Lucid Diagnostics (LUCD) position steady in Q3 2026 at 58,590 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #224.

Traphagen Investment Advisors first reported a position in LUCD in Q2 2025 and has held it in 6 quarters since. The position peaked at $62.7K in Q2 2026. 9 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

  • Traphagen Investment Advisors held 58,590 shares of Lucid Diagnostics worth $44K as of Q3 2026.
  • Traphagen Investment Advisors left its Lucid Diagnostics share count unchanged in Q3 2026.
  • Lucid Diagnostics made up ﹤0.01% of Traphagen Investment Advisors's portfolio in Q3 2026, its #224 holding.
  • Traphagen Investment Advisors first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 6 quarters since.
  • Traphagen Investment Advisors's Lucid Diagnostics position peaked at $62.7K in Q2 2026.
  • 9 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on Traphagen Investment Advisors's 13F filing for Q3 2026, filed 14 Oct 2026.